newsfilter
← Latest News
Business Wire·

Korro Bio and Frequency Therapeutics Announce Merger Agreement

Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio's wholly owned portfolio of RNA editing programs Lead program is a disease modifying therapy for patients with alpha-1